Abstract: The invention includes halichondrin B analogs having pharmaceutical activity; in some cases, crystalline forms thereof, and in some cases, halichondrin B analogs having a further utility as synthetic intermediate.
Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
Type:
Grant
Filed:
April 24, 2013
Date of Patent:
December 8, 2015
Assignee:
Theravance Biopharma R&D IP, LLC
Inventors:
Daniel D. Long, Robert Murray McKinnell, Lori Jean Van Orden, Gavin Ogawa, Donna Wilton
Abstract: Systems and methods for integrating quantum computing systems into mobile systems for the purpose of providing real-time, quantum computer-based control of the mobile systems are described. A mobile system includes a data extraction subsystem that extracts data from an external environment of the mobile system and a quantum computing subsystem that receives data from the data extraction subsystem and performs a quantum computing operation in real-time using the data from the data extraction subsystem. A result of the quantum computing operation influences a behavior of the mobile system, such as the navigation of the mobile system or an action performed by the mobile system. The on-board quantum computing subsystem includes on-board quantum computing infrastructure that is adapted to suit the needs and spatial constraints of the mobile system.
Abstract: A geo-fencing system includes a plurality of beacons defining zones within a venue. The system receives a first beacon identifier from a mobile device and registers the mobile device in a first zone corresponding to the first beacon. The system causes a first menu to be displayed on the mobile device, indicating options for the first zone. In response to selection of one of the options, the system registers the mobile device as being active in the first zone. The system then receives a second beacon identifier and registers the mobile device as being in the second zone. The system also suspends the activity of the mobile device in the first zone and causes options to be displayed to continue or terminate the activity in the first zone.
Abstract: In a method of configuring a host device in a process control plant to automatically perform an action or a set of actions includes, a workflow template is generated. The workflow template includes a sequence of one or more steps to be performed by the host device. Each of at least some of the one or more steps is selected from a set of predetermined steps. Then, an instance of the workflow template is generated at the host device. A trigger condition is generated for automatically triggering the instance workflow. The sequence of the one or more steps is executed in response to detecting the trigger condition.
Abstract: Due to size and cost, it becomes advantageous for integrated circuit (IC) manufacturers to use “single-ended” (one signal path per unique information path) high speed signals electrical contact pins (pins transmitting digital information that connect the integrated circuit to a printed circuit board) with a minimum number of surrounding powers and grounds. This lower cost method, however, creates electrical interference and coupling issues known as crosstalk between two adjacent signal paths in the via structure required to electrically connect the integrated circuit to the signal paths in the printed circuit board. Such crosstalk, in turn, increases jitter, degrades timing, and ultimately reduces the maximum operating speed of the circuit (performance). This disclosure presents a structure using micro-plating, micro-drilling and micro-machining methods that isolates adjacent signals by placing a metal barrier that shunts coupling currents to ground.
Abstract: Disclosed is a cosmetic composition comprising a first film-forming polymer having a contact angle of at least 85°, a second film-forming polymer having a contact angle of at least 85°, a lipid having a melting point of at least 5° C., optical particle, and at least 20% of water by weight of the composition.
Abstract: A method and device for treating an infection of the nail or nail bed and adjacent tissues through non-thermal means is described. The device illuminates an area with light in the near-infrared region of the electromagnetic spectrum. Preferably, light having wavelengths of from about 870 nm to about 930 nm will be used. Further, the device includes light emitting diodes that are capable of emitting ultraviolet light. These lights are intended to provide a sterile environment for a user using the apparatus.
Type:
Application
Filed:
May 29, 2015
Publication date:
December 3, 2015
Applicant:
New Skin Therapies, LLC, d/b/a/ NST Consulting, LLC
Inventors:
Raymond R. Blanche, Raymond J. Lanzafame, David J. Smith
Abstract: A system may be configured to receive profile identifiers from a set of user devices; identify, based on the profile identifiers, one or more user devices, of the set of user devices, for which updated parameters should be provided, the parameters relating to operation of the one or more user devices with respect to a telecommunications network; and provide, to the identified one or more user devices, the updated parameters.
Abstract: The present invention provides relates to an edible composition for anti-diabetic benefit. Diabetes is one of the major and commonly occurring health problems in today's world. Pharmaceuticals companies are very active in this field to develop new medicines for preventing and controlling diabetes. There are several medicines available in the market for the treatment of type 2 diabetes. There are prior arts which describes composition and/or therapies for the prevention of glucose intolerance and/or diabetes. We have found that, though prior art discloses compositions and therapies for treating diabetes, there is not disclose any food composition which is effectively controls GLP-1 activity thereby control diabetes.
Type:
Application
Filed:
November 26, 2013
Publication date:
December 3, 2015
Applicant:
Conopco, Inc., d/b/a UNILEVER
Inventors:
Nandini Balaram Singh, Gautam Banerjee, Willemina Albertha M. Blom, Robertus Johannes Gouka, Ramitha Kalathil, Suman Majumder
Abstract: A system and method for sub-renting a vehicle to a secondary/sub-renter after the vehicle has been rented to a primary renter. The vehicle may comprise a telematics control unit to enhance the sub-renting process. A rental duration of secondary renter(s) may be compared to an idle timeframe specified by the primary renter. Other rental parameters may be compared to enhance sub-renting of the vehicle, such as an idle location and a vehicle class of the vehicle, for example. In this manner, rented vehicles can be utilized more, particularly during periods when the primary renter has no need to use the rented vehicle. Secondary renters are enabled to use/rent the vehicle during these idle periods and the primary renter can avoid paying for more than he or she needs.
Abstract: The present invention relates to a kit for preparing a beverage in a beverage preparation machine, the kit comprising at least one filter pod containing one or more soluble or extractable beverage ingredients and a separate porous sheet provided with a soluble flavouring ingredient.
Abstract: The present invention relates to a method of assessing proprioceptive status by calculating a proprioceptive score Sp from absolute and variable errors between target angles and angles estimated and joint motion detection by the person tested, and/or between measured time of perceived movement of the joint of the tested person these proprioceptive scores of a person being associated with an assessment date and then stored with a date so as to serve as a reference when said person is monitored or when there is a comparison of said person with at least another person. The present invention also concerns an apparatus for the proprioceptive assessment of at least one joint, this apparatus having two movable parts (8, 9) with drive means (12, 15) particular for the pivoting of the movable parts (8, 9), means of determining the pivot angle for each of the first and second parts (8, 9) also being provided. Applications are in the field of proprioceptive assessment by movement of a limb of a person.
Type:
Application
Filed:
December 30, 2013
Publication date:
December 3, 2015
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AIX MARSEILLE, ASSISTANCE PUBLIQUE DES HOPITAUX DE MARSEILLE
Inventors:
Pascale Rabischong, Patrick Sainton, Violaine Sevrez, Joël Coste
Abstract: The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocyte cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocyte cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocyte cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein.
Type:
Grant
Filed:
December 28, 2012
Date of Patent:
December 1, 2015
Assignees:
Institut Pasteur, Ecole Nationale Veterinaire D'Alfort, Institut Curie, Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique (INRA)
Abstract: The invention is directed to compounds having the formula: wherein: Ar, r, n, X, R2-3 and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
Type:
Grant
Filed:
December 18, 2013
Date of Patent:
December 1, 2015
Assignee:
Theravance Biopharma R&D IP, LLC
Inventors:
Paul Allegretti, Seok-Ki Choi, Paul R. Fatheree, Roland Gendron, Ryan Hudson, Keith Jendza, Robert Murray McKinnell, Darren McMurtrie, Brooke Olson
Abstract: A memory access arbiter (MAA) in an RFID tag is connected to an unique address space (UAS), which comprises a non-volatile memory (NVM), a transferred data memory (TDM) and a status-information memory (SIM) storing information on the status of the transferred data memory (TDM). The transferred data memory (TDM) and the status-information memory (SIM) are volatile memories, e.g. of the RAM type having a memory capacity of 16 bits or 32 bits according to the standard of an applied RFID communication. The RFID tag of the invention provides for a faster communication between an interrogator and an external logic element by one order of magnitude, which is due to fast volatile memories for transferred data as well as for corresponding status information. A still higher communication rate is achieved by introducing a command that has not yet been standardized.
Type:
Grant
Filed:
February 23, 2010
Date of Patent:
December 1, 2015
Assignee:
AMS R&D D.O.O.
Inventors:
Kosta Kovacic, Vinko Kunc, Andrej Vodopivec
Abstract: A hinge assembly for vehicle seat, comprising first, second, and third frames assembled to pivot, a hinge mechanism for adjusting an angular usage position of the first frame relative to the third frame, a first lock to immobilize the first frame relative to the third frame in said usage position, and a first control device for releasing the first lock is disclosed. It also comprises a second lock to immobilize the first frame relative to the second frame in a tilted position, a stop to immobilize the first frame in the tilted position, and a second control device for releasing the second lock.
Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies.